• Je něco špatně v tomto záznamu ?

Sustained circulation of enterovirus D68 in Europe in 2023 and the continued evolution of enterovirus D68 B3-lineages associated with distinct amino acid substitutions in VP1 protein

A. Hirvonen, CK. Johannesen, P. Simmonds, TK. Fischer, H. Harvala, KSM. Benschop, ENPEN study collaborators

. 2025 ; 178 (-) : 105785. [pub] 20250405

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015493

BACKGROUND: Enterovirus D68 (EV-D68) causes respiratory disease ranging from mild to severe and in rare cases a paralytic syndrome, called acute flaccid myelitis (AFM). Since the global EV-D68 outbreak in 2014, the virus has mainly circulated in biennial epidemic cycles with peaks detected during even years. However, following the COVID-19 pandemic, the seasonal pattern of EV-D68 has been characterized by large yearly upsurges. Here, we describe the circulation of EV-D68 in Europe in 2023 and track its genetic evolution. STUDY DESIGN: Data was compiled from members of the European Non-Polio Network (ENPEN). This included monthly data on the total number of EV samples tested, EV positive samples, EV-D68 positive samples and cases, and other EV positive samples detected in 2023. Information on sample types and surveillance system was recorded. Sequence data from the VP1 gene was used for phylogenetic and amino acid sequence analysis. RESULTS: EV was detected in 13,585 out of 203,622 diagnostic samples tested (6.7 %), of which 402 (3.0 %) were determined as EV-D68, representing 386 cases. EV-D68 infections peaked in October 2023 (136/386; 35.2 %). 267/386 (69.2 %) of EV-D68 cases were captured through clinical EV surveillance, almost all of which (202/204 of positive samples with sample type information) were detected in respiratory specimens. Phylogenetic analysis performed on 99 VP1 sequences revealed a distinct B3-derived lineage with a previously undescribed residue change, D554E, in Europe. CONCLUSIONS: The study documents sustained circulation of EV-D68 in Europe in 2023, the evolution of B3-derived lineages, and appearance of previously undescribed amino acid substitutions in Europe. This stresses the need for continuous EV-D68 surveillance and harmonization of EV-D68 detection practices towards better data comparability across countries.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015493
003      
CZ-PrNML
005      
20250731091025.0
007      
ta
008      
250708e20250405ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcv.2025.105785 $2 doi
035    __
$a (PubMed)40215651
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Hirvonen, Aurora $u Laurea University of Applied Sciences, Vantaa, Finland
245    10
$a Sustained circulation of enterovirus D68 in Europe in 2023 and the continued evolution of enterovirus D68 B3-lineages associated with distinct amino acid substitutions in VP1 protein / $c A. Hirvonen, CK. Johannesen, P. Simmonds, TK. Fischer, H. Harvala, KSM. Benschop, ENPEN study collaborators
520    9_
$a BACKGROUND: Enterovirus D68 (EV-D68) causes respiratory disease ranging from mild to severe and in rare cases a paralytic syndrome, called acute flaccid myelitis (AFM). Since the global EV-D68 outbreak in 2014, the virus has mainly circulated in biennial epidemic cycles with peaks detected during even years. However, following the COVID-19 pandemic, the seasonal pattern of EV-D68 has been characterized by large yearly upsurges. Here, we describe the circulation of EV-D68 in Europe in 2023 and track its genetic evolution. STUDY DESIGN: Data was compiled from members of the European Non-Polio Network (ENPEN). This included monthly data on the total number of EV samples tested, EV positive samples, EV-D68 positive samples and cases, and other EV positive samples detected in 2023. Information on sample types and surveillance system was recorded. Sequence data from the VP1 gene was used for phylogenetic and amino acid sequence analysis. RESULTS: EV was detected in 13,585 out of 203,622 diagnostic samples tested (6.7 %), of which 402 (3.0 %) were determined as EV-D68, representing 386 cases. EV-D68 infections peaked in October 2023 (136/386; 35.2 %). 267/386 (69.2 %) of EV-D68 cases were captured through clinical EV surveillance, almost all of which (202/204 of positive samples with sample type information) were detected in respiratory specimens. Phylogenetic analysis performed on 99 VP1 sequences revealed a distinct B3-derived lineage with a previously undescribed residue change, D554E, in Europe. CONCLUSIONS: The study documents sustained circulation of EV-D68 in Europe in 2023, the evolution of B3-derived lineages, and appearance of previously undescribed amino acid substitutions in Europe. This stresses the need for continuous EV-D68 surveillance and harmonization of EV-D68 detection practices towards better data comparability across countries.
650    _2
$a lidé $7 D006801
650    12
$a lidský enterovirus D $x genetika $x klasifikace $x izolace a purifikace $7 D030016
650    12
$a enterovirové infekce $x epidemiologie $x virologie $7 D004769
650    _2
$a substituce aminokyselin $7 D019943
650    _2
$a fylogeneze $7 D010802
650    _2
$a molekulární evoluce $7 D019143
650    12
$a virové plášťové proteiny $x genetika $7 D036022
650    _2
$a COVID-19 $x epidemiologie $7 D000086382
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
700    1_
$a Johannesen, Caroline Klint $u Department of Clinical Research, Nordsjællands Hospital, Hillerød, Denmark
700    1_
$a Simmonds, Peter $u Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
700    1_
$a Fischer, Thea K $u Department of Clinical Research, Nordsjællands Hospital, Hillerød, Denmark; Pandemix Center for Excellence, Roskilde University, Roskilde, Denmark; Department of Public Health, University of Copenhagen, Copenhagen, Denmark
700    1_
$a Harvala, Heli $u Microbiology Services, National Health Service (NHS) Blood and Transplant, London, United Kingdom; Institute of Biomedicine, University of Turku, Finland; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
700    1_
$a Benschop, Kimberley S M $u Centre for Infectious Disease Research, Diagnostics and Laboratory Surveillance (IDS), National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Electronic address: kim.benschop@rivm.nl
710    2_
$a ENPEN study collaborators
773    0_
$w MED00005010 $t Journal of clinical virology $x 1873-5967 $g Roč. 178 (20250405), s. 105785
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40215651 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091019 $b ABA008
999    __
$a ok $b bmc $g 2366374 $s 1252618
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 178 $c - $d 105785 $e 20250405 $i 1873-5967 $m Journal of clinical virology $n J Clin Virol $x MED00005010
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace